Ovid Therapeutics (OVID) Other financing activities (2017 - 2026)

Ovid Therapeutics (OVID) has reported Other financing activities for 10 consecutive years, with -$3.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other financing activities changed N/A year-over-year to -$3.6 million; the trailing twelve-month figure through Jun 2026 stood at $131.3 million (up 257325.49% YoY), and the FY2025 full-year result was $75.1 million, up 11976.53% from the prior year.
• Other financing activities retreated to -$3.6 million in Q2 2026 per OVID's latest filing, from $59.8 million in the prior quarter.
• Across five years, Other financing activities topped out at $75.1 million in Q4 2025 and bottomed at -$3.6 million in Q2 2026.
• Historically, Other financing activities has averaged $8.3 million across 5 years, with a median of $74314.5 in 2022.
• The sharpest annual moves came in 2022 and 2026: Other financing activities tumbled 113.89% in 2022, then jumped 459923.08% in 2026.
• Over 5 years, Other financing activities stood at -$43599.0 in 2022, then jumped by 175.69% to $33000.0 in 2023, then climbed by 15.15% to $38000.0 in 2024, then jumped by 197500.0% to $75.1 million in 2025, then plunged by 104.82% to -$3.6 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered -$3.6 million, $59.8 million, and $75.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.